Why Pharma Isn’t Investing in AMR Research & Why Public Awareness Matters

In this video from our latest മലയാളം Health Commune podcast, Dr. Aravind R discusses why pharmaceutical companies are showing limited interest in antimicrobial resistance (AMR) research and why the government is stepping in to priortise it. He explains how humans and microbes like bacteria are in a constant race, with bacteria gaining the upper hand. This growing threat makes it urgent to develop new antibiotics before existing ones gain resistance.

Dr. Aravind also highlights the increasing importance of research in the field of diagnostics, as well as improving access to diagnostic tools. He emphasises the need for a comprehensive, multimodal strategy to combat AMR, along with the critical role of public awareness in preventing the overuse, misuse, and abuse of antibiotics.

WRITTEN BY

Dr. Aravind R

As an expert in Infectious Diseases and a public health strategist, Dr. Aravind has played a crucial role in combating antimicrobial resistance (AMR) through several campaigns, initiatives and programmes. He is one of the key architects behind the Antibiotic Smart Hospitals Initiative (ASHI), as well as KARSAP, the state’s action plan to combat AMR.